Hedge Funds Cashed Out Of Amicus Therapeutics, Inc. (FOLD) Too Early
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November.
Posts Tagged ‘NASDAQ:FOLD’
Were Hedge Funds Right About Souring On Amicus Therapeutics, Inc. (FOLD)?
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing.
Is Amicus Therapeutics, Inc. (FOLD) A Good Stock To Buy?
Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could...
Amicus Therapeutics, Inc. (FOLD) Hedge Funds Are Snapping Up
The fourth quarter was a rough one for most investors, as fears of a rising interest rate environment in the U.S, a trade war with China, and a more or less stagnant Europe, weighed...
Hedge Fund and Insider Trading News: Warren Buffett, Elliott Management, Mcdonald’s Corp (MCD), GTT Communications Inc (GTT), Butler National Co. (BUKS), and More
Warren Buffett’s Berkshire Hathaway Inc. is hopping on the fintech bandwagon.
Hedge Fund and Insider Trading News: Ken Griffin, Carl Icahn, Howard Hughes Corp (HHC), Amicus Therapeutics, Inc. (FOLD), Falcon Minerals Corp (FLMN), and More
Billionaire Ken Griffin hired two veteran money managers from Louis Bacon’s hedge fund as he seeks to build a rival macro business.
Hedge Fund and Insider Trading News: Bill Miller, John Paulson, Warren Buffett, Amicus Therapeutics, Inc. (FOLD), Workday Inc (WDAY), and More
Famed investor Bill Miller is still a believer in Facebook. "This too will pass," he said in an email to CNBC's Scott Wapner.
Amicus Therapeutics, Inc. (FOLD) Could Be The Force That Brings Change To The FDA
President Donald Trump in his inaugural speech to a joint session of Congress characterized the approval process of drugs at the U.S.
Amicus Therapeutics, Inc. (FOLD) Announces The Closure Of Its Senior Convertible Notes
Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. (FOLD): Breaking Down The Raise
Amicus Therapeutics, Inc. (NASDAQ:FOLD) just announced a convertible senior notes offering, and the company is trending down on he back of the news.
Is Amicus Therapeutics, Inc. (FOLD) A Good Stock To Buy?
Hedge funds run by legendary names like Nelson Peltz and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to...
Biotech Movers And Shakers: Nivalis Therapeutics Inc (NVLS) And Amicus Therapeutics, Inc. (FOLD)
It’s time to take a look at those stocks that really moved over the last twenty-four hours or so in biotech, and there are plenty to go at.
Is Redmile Group Right to Bet on Array Biopharma Inc (ARRY), Amicus Therapeutics, Inc. (FOLD) & Two Other Stocks?
Despite of all the negative sentiment looming around them, hedge funds had a pretty solid run for much of this year, generating positive returns for seven or eight consecutive...
Biotech Gainers On Tuesday: Amicus Therapeutics, Inc. (FOLD) And Ionis Pharmaceuticals Inc (IONS)
While wider markets turn there focus to the US elections, the biotech space is alive and well, and after a tough end to last week, a number of companies have enjoyed gains throughout...
Big Bet on Sarepta Therapeutics Inc (SRPT) Lifts Perceptive Advisors’ Q3 Returns; See How Other Investments Performed
Joseph Edelman's Perceptive Advisors is a fund that has an equity portfolio worth $1.44 billion as of the end of June, with over 80% of it being invested in healthcare stocks.
Five Cheap Healthcare Stocks Poised to Explode
The healthcare sector has witnessed a significant correction in the last 15 months, with many prominent names in the industry losing a noteworthy chunk of their market capitalization...
Redmile Group Sticking With Healthcare Picks After Rough Q1
Redmile Group is a San Francisco-based, healthcare-focused hedge fund founded and managed by Jeremy Green, an Oxford alum with more than 20 years of experience in wealth management...
Amicus Therapeutics, Inc. (FOLD): Small-Cap Biotech with Large Hedge Fund Ownership
Amicus Therapeutics, Inc. (NASDAQ:FOLD)'s lead drug candidate is migalastat, which targets Fabry disease.
Why Are Investors Excited About These 5 Stocks Today?
The markets are going nowhere today, after the IMF cut its global growth forecast for the fourth time over the past twelve months, due to China's slowdown.
Why Valeant, Micron, and Three Other Stocks Are in Green Territory on Friday?
Oil went back to tumbling on Friday, with crude oil losing more than 3.5%. On the other hand, markets returned to positive territory, with major U.S.
Top Biotech Picks of Best-Performing Hedge Fund of 2015
Bloomberg recently came out with its list of best performing hedge funds of 2015 and the fund that managed to beat all its rivals and emerge at the top of the list was biotech...
Redmile Group’s Top Q4 Moves as Its Long Positions Show Gains of 20% in 2015
Redmile Group is a San Francisco-based investment firm managed by Jeremy Green, which primarily focuses on the healthcare sector.
Five Cheap Healthcare Stocks Poised to Explode
Over the past few months the healthcare sector has undergone a roller coaster of a ride, especially in August and September when many investors got wary of the sector being overvalued...
The Smart Money Is Hoarding Shares of These 10 Healthcare Stocks: Part 1
Given elite hedge funds have filed their latest 13F's, we have an opportunity to analyze what hedge funds like and what they don't like.
Are Hedge Funds Dumping Amicus Therapeutics, Inc. (FOLD)?
The third-quarter stock market correction has turned out to resemble the situation observed during the Asian financial crisis of 1997.
Why Are These Four Stocks Making A Late Surge?
Shareholders of Amicus Therapeutics, Inc. (NASDAQ:FOLD), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Novavax, Inc.
Are The Gains In These Hot Monday Stocks Sustainable?
It’s a good Monday for investors of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV), Amicus Therapeutics, Inc. (NASDAQ:FOLD), and Oasis Petroleum Inc.
Something that Might Change Your Mind About Two of These Three Falling Stocks
Three stocks trending significantly low today before afternoon were Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. (FOLD), Neurocrine Biosciences, Inc. (NBIX), and Retrophin Inc (RTRX) among Biotech Guru Joseph Edelman’s Top Healthcare Picks
Biotech Guru Joseph Edelman's Perceptive Advisors is known for its long-short investment approach that focuses on biotech stocks.
Tuesday Morning Corporation (TUES), Swift Transportation Co (SWFT), Amicus Therapeutics, Inc. (FOLD): Citadel’s Latest Moves
Ken Griffin's Citadel Investment Group has increased its stakes in Tuesday Morning Corporation (NASDAQ:TUES), Swift Transportation Co (NYSE:SWFT), and Amicus Therapeutics, Inc...
Amicus Therapeutics, Inc. (FOLD): Redmile Group Trims Position and Books Some Profits from Long-Term Investment
Jeremy Green's Redmile Group has also reduced its stake in Amicus Therapeutics, Inc.
Amicus Therapeutics Inc. (FOLD): Palo Alto Investors Sells Half of its Stake At Sky-High Valuation
William Leland Edwards’ Palo Alto Investors disclosed today a 50% decrease in its exposure to Amicus Therapeutics, Inc. (NASDAQ:FOLD).
Perceptive Advisors Buys 4.0 Million Shares Of Amicus Therapeutics Inc. (FOLD)
Perceptive Advisors, managed by Joseph Edelman, is bullish on Amicus Therapeutics Inc. (NASDAQ:FOLD). In a new filing with the U.S.
Jeremy Green, Redmile Group Boost Position in Amicus Therapeutics, Inc. (FOLD)
Jeremy Green's Redmile Group has significantly surged its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD), a new filing with the SEC revealed.
Hedge Funds Are Selling BioDelivery Sciences International, Inc. (BDSI)
At the moment, there are many indicators market participants can use to watch their holdings. Two of the most under-the-radar are hedge fund and insider trading activity.
This Metric Says You Are Smart to Buy Amicus Therapeutics, Inc. (FOLD)
Now, according to many investors, hedge funds are assumed to be overrated, outdated investment tools of an era lost to time.
Pain Therapeutics, Inc. (PTIE): Are Hedge Funds Right About This Stock?
In the eyes of many investors, hedge funds are viewed as overrated, old investment vehicles of an era lost to time.
Hedge Funds Are Buying ZIOPHARM Oncology Inc. (ZIOP)
In the eyes of most stock holders, hedge funds are seen as underperforming, outdated financial vehicles of years past.
Hedge Funds Are Buying Amicus Therapeutics, Inc. (FOLD)
Amicus Therapeutics, Inc. (NASDAQ:FOLD) was in 12 hedge funds' portfolio at the end of March.
Is BioDelivery Sciences International, Inc. (BDSI) Going to Burn These Hedge Funds?
BioDelivery Sciences International, Inc.
Pain Therapeutics, Inc. (PTIE): Are Hedge Funds Right About This Stock?
Is Pain Therapeutics, Inc. (NASDAQ:PTIE) a buy, sell, or hold? The smart money is in a bearish mood.
Amicus Therapeutics, Inc. (FOLD): Are Hedge Funds Right About This Stock?
Is Amicus Therapeutics, Inc. (NASDAQ:FOLD) a marvelous investment today? Money managers are becoming less confident.
Are These 3 Stocks Down for the Count?: Ruckus Wireless Inc (RKUS) and More
Horse meat and Wal-Mart Stores, Inc.
This Week in Biotech: AbbVie Inc (ABBV) and More
With the SPDR S&P Biotech Index up 20% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
3 Horrendous Health-Care Stocks This Week: Amicus Therapeutics, Inc. (FOLD) and More
The Ides of March meant bad news for Julius Caesar. Similarly, the week surrounding the Ides of February haven't turned out so well for several health-care stocks.
Issuing More Shares: Good or Bad? – Buckeye Partners, L.P. (BPL), Citigroup Inc. (C) and More
Buckeye Partners, L.P. (NYSE:BPL) recently announced plans to issue additional limited partnership units. Citigroup Inc.
